• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

Opinion
Video

Panelists discuss how ideal candidates for amyloid-targeting therapy typically present with biomarker-confirmed early-stage Alzheimer disease, demonstrate positive amyloid PET scans or CSF biomarkers, exhibit mild cognitive impairment or mild dementia, lack contraindications such as significant cerebrovascular disease or anticoagulant use, have adequate support systems for monitoring and managing potential adverse effects, and would benefit from comprehensive pretreatment evaluations including brain MRI and APOE genotyping.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Could you describe the profile of a patient who would be a candidate for treatment with amyloid-targeting therapy?

      Related Content
      © 2025 MJH Life Sciences
      AJMC®
      All rights reserved.